Return to homepagePandemic Pact

Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93021C00054-0-9999-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $598,808

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Omer Rasheed

  • Research Location

    United States of America

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The long-term goal of the program is the commercial development of synthetic mimetics of novel saponin adjuvants that can be produces as single chemical entities on a large scale, are chemically more stable than current saponin adjuvants.